30 Jul Clinical Research in APAC: Why the Center of Gravity Keeps Shifting East
For years, Asia-Pacific was described as an “emerging” clinical trial region. That label no longer fits. APAC has become a structural pillar of global clinical development — and for sponsors and CROs planning their next programs, the question is no longer whether to include the region, but how to do it right.
A market growing twice as fast as the global average
The numbers tell a clear story. The Asia-Pacific clinical trials market was valued at USD 16.82 billion in 2024 and is projected to nearly double to USD 34.23 billion by 2033, a CAGR of 8.46% (Grand View Research). The region’s trajectory is long in the making: APAC’s share of global trial volume already jumped from 5.9% in 2005–2007 to nearly 10% by 2011, and the momentum has only accelerated since.
Three forces drive that growth: patient access, speed, and — increasingly — regulatory competitiveness.
The enrollment advantage is real
Asia is home to roughly 60% of the world’s population, with vast urban centers, high unmet medical needs, and large treatment-naïve patient pools. That translates into measurable operational gains. Trial density remains far lower than in the West — for non-Hodgkin lymphoma, about 0.4 recruiting sites per million urban residents versus 3.8 in the US — meaning less competition for the same patients. Median enrollment timelines run faster (23.1 months in APAC versus 25.5 in the US), with roughly double the monthly recruitment rates.
Speed compounds into commercial value. As Pramod Kashid, CEO of the APAC-focused CRO Expecto, put it at a January 2026 Citeline roundtable: “We’ve had trials where we enrolled 50% of the global patient population from the APAC region and accelerated marketing authorization by one year.”
There is a second, strategic dividend: diversity. With regulators like the US FDA formalizing expectations for representative trial populations, APAC’s ethnic and genetic diversity has become a compliance asset, not just a recruitment one.
A shifting map within the region
APAC is not one market — and the internal hierarchy is moving fast.
India has become the region’s growth engine, with trial initiations rising from 741 in 2014 to 1,710 in 2024 — overtaking Japan. Cost efficiency, a deep patient pool, and a maturing CDMO ecosystem are pulling global programs in.
Japan, despite declining initiation volumes (1,834 in 2014 to 1,115 in 2024), is repositioning around high-value science: cell and gene therapy, rare disease, and early-phase oncology, backed by AMED funding and PMDA regulatory innovation.
South Korea grew from 881 to 1,151 trials over the same decade, ranked among the world’s top clinical trial nations thanks to advanced hospital networks and famously fast patient recruitment.
China remains the region’s largest market — and just removed one of its historic friction points. In late 2025, the NMPA rolled out a nationwide 30-day IND review pathway for innovative drugs, bringing study start-up timelines in line with, or ahead of, Western benchmarks.
Australia continues to punch above its weight in early phase, combining a generous R&D tax incentive, FDA acceptance of Australian data, and mature Phase I infrastructure. Singapore, Taiwan, Malaysia, and Thailand round out the map with targeted incentives — from Taiwan’s extended market exclusivity for global trials to Singapore’s national patient-matching initiatives.
Regulators are competing for trials
Perhaps the most underappreciated trend: APAC regulators are now actively competing to attract clinical research. China’s 30-day IND is the headline, but the pattern is regional — Taiwan published Asia’s first decentralized clinical trial (DCT) guidance in 2023, Japan’s MHLW has been building guidance for direct-to-patient drug shipment and e-consent, and Australia’s TGA formally supports remote visits and e-consenting. Patient readiness is ahead of the curve too: in one IQVIA survey at a major Chinese hospital, 89% of patients considered decentralized trial elements acceptable.
The catch: APAC rewards preparation, punishes assumptions
None of these advantages are evenly distributed. Standards of care, investigator incentives, digital infrastructure, and patient awareness vary enormously between — and within — countries. Trial designs that ignore local realities fail: a celiac protocol built around bread challenges in rice-eating populations, or an Alzheimer’s program planned for a market that lacked the required specialty infrastructure, are real cautionary tales from experienced operators.
The consistent lesson from sponsors who succeed in the region: engage local investigators early on protocol design, and partner with organizations that have genuine on-the-ground expertise in each market. In APAC, local knowledge is not a nice-to-have — it is the difference between the region’s speed advantage materializing or evaporating.
The bottom line
APAC now offers what global drug development needs most: patients, speed, diversity, and increasingly competitive regulators. The sponsors who win there treat it not as a rescue strategy for slow-enrolling trials, but as a first-line region — designed in from the start, with the right partners on the ground.
Sources:
Grand View Research, Asia Pacific Clinical Trials Market Report; Citeline/Norstella roundtables (2023, 2026);
Clinical Trials Arena; ObvioHealth/IQVIA; Yathindranath et al., Open Access Journal of Clinical Trials (2014);
NMPA Announcement [2025] No. 86.
No Comments